Cargando…

Molecular and pharmacological chaperones for SOD1

The efficacy of superoxide dismutase-1 (SOD1) folding impacts neuronal loss in motor system neurodegenerative diseases. Mutations can prevent SOD1 post-translational processing leading to misfolding and cytoplasmic aggregation in familial amyotrophic lateral sclerosis (ALS). Evidence of immature, wi...

Descripción completa

Detalles Bibliográficos
Autor principal:	Wright, Gareth S.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2020
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458393/ https://www.ncbi.nlm.nih.gov/pubmed/32794552 http://dx.doi.org/10.1042/BST20200318

Ejemplares similares

Molecular recognition and maturation of SOD1 by its evolutionarily destabilised cognate chaperone hCCS
por: Sala, Fernanda A., et al.
Publicado: (2019)

A copper chaperone–mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis
por: McAlary, L., et al.
Publicado: (2022)

Ligand binding and aggregation of pathogenic SOD1
por: Wright, Gareth S.A., et al.
Publicado: (2013)

A molecular chaperone activity of CCS restores the maturation of SOD1 fALS mutants
por: Luchinat, Enrico, et al.
Publicado: (2017)

Galactosemia: Towards Pharmacological Chaperones
por: Banford, Samantha, et al.
Publicado: (2021)

Chaperone-Mediated Autophagy in Neurodegenerative Diseases: Molecular Mechanisms and Pharmacological Opportunities
por: Wang, Yi-Ting, et al.
Publicado: (2022)

Pharmacological chaperone therapy for Fabry disease
por: ISHII, Satoshi
Publicado: (2012)

Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses
por: Losada Díaz, Juan Camilo, et al.
Publicado: (2019)

Pharmacological Chaperone Therapy for Pompe Disease
por: Borie-Guichot, Marc, et al.
Publicado: (2021)

Second-Generation Pharmacological Chaperones: Beyond Inhibitors
por: Tran, My Lan, et al.
Publicado: (2020)

Molecular Chaperone Mediated Late-Stage Neuroprotection in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis
por: Novoselov, Sergey S., et al.
Publicado: (2013)

A faulty interaction between SOD1 and hCCS in neurodegenerative disease
por: Wright, Gareth S. A., et al.
Publicado: (2016)

Chaperone-Dependent Mechanisms as a Pharmacological Target for Neuroprotection
por: Voronin, Mikhail V., et al.
Publicado: (2023)

Quantifying the Interaction between Copper-Zinc Superoxide Dismutase (Sod1) and its Copper Chaperone (Ccs1)
por: Boyd, Stefanie D, et al.
Publicado: (2018)

Mutations in Superoxide Dismutase 1 (Sod1) Linked to Familial Amyotrophic Lateral Sclerosis Can Disrupt High-Affinity Zinc-Binding Promoted by the Copper Chaperone for Sod1 (Ccs)
por: Boyd, Stefanie D., et al.
Publicado: (2020)

4-Hexylresorcinol: pharmacologic chaperone and its application for wound healing
por: Kim, Seong-Gon
Publicado: (2022)

Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones
por: Underhaug, Jarl, et al.
Publicado: (2012)

Molecular Chaperones and Thyroid Cancer
por: Paladino, Letizia, et al.
Publicado: (2021)

The molecular chaperon AKR2A increases the mulberry chilling-tolerant capacity by maintaining SOD activity and unsaturated fatty acids composition
por: Chen, Lin, et al.
Publicado: (2018)

Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology
por: Grasso, Daniela, et al.
Publicado: (2023)

Pharmacological Chaperones Attenuate the Development of Opioid Tolerance
por: Okuyama, Youta, et al.
Publicado: (2020)

Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase
por: Bendikov-Bar, Inna, et al.
Publicado: (2013)

Molecular chaperones and selection against mutations
por: Tomala, Katarzyna, et al.
Publicado: (2008)

Molecular chaperones and hypoxic-ischemic encephalopathy
por: Hua, Cong, et al.
Publicado: (2017)

Molecular chaperones in stroke-induced immunosuppression
por: Qiao, Haoduo, et al.
Publicado: (2023)

Targeted stabilization of Munc18‐1 function via pharmacological chaperones
por: Abramov, Debra, et al.
Publicado: (2020)

Differential Interactions of Molecular Chaperones and Yeast Prions
por: Barbitoff, Yury A., et al.
Publicado: (2022)

Copper Sources for Sod1 Activation
por: Boyd, Stefanie D., et al.
Publicado: (2020)

Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations
por: Liguori, Ludovica, et al.
Publicado: (2020)

Design and synthesis of biologically active carbaglycosylamines: From glycosidase inhibitors to pharmacological chaperones
por: OGAWA, Seiichiro, et al.
Publicado: (2022)

Azasugar inhibitors as pharmacological chaperones for Krabbe disease
por: Hill, Chris H., et al.
Publicado: (2015)

Roles of molecular chaperones in protein degradation
Publicado: (1996)

ATP-Driven Molecular Chaperone Machines
por: Clare, Daniel K, et al.
Publicado: (2013)

Q&A: What are pharmacological chaperones and why are they interesting?
por: Ringe, Dagmar, et al.
Publicado: (2009)

Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues
por: Lallier, Morgane, et al.
Publicado: (2021)

A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria
por: Bustad, Helene J., et al.
Publicado: (2020)

The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation
por: Capper, Michael J., et al.
Publicado: (2018)

Pharmacological inhibition of ALCAT1 mitigates amyotrophic lateral sclerosis by attenuating SOD1 protein aggregation
por: Liu, Xueling, et al.
Publicado: (2022)

Drug repositioning can accelerate discovery of pharmacological chaperones
por: Hay Mele, Bruno, et al.
Publicado: (2015)

Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones
por: Sutton, Charles, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2cri1ailda53qfieo524nhkvvh